Compare · NVO vs SVRA
NVO vs SVRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Savara Inc. (SVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 187.3x SVRA ($1.15B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for SVRA).
- NVO has more recent analyst coverage (25 ratings vs 10 for SVRA).
- Company
- Novo Nordisk A/S
- Savara Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $1.15B
- 1M return
- -
- +3.13%
- 1Y return
- -
- +68.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 5
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Savara Inc.
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SVRA
- Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
- Savara Announces New Employment Inducement Grant
- SEC Form S-8 filed by Savara Inc.
- SEC Form 10-Q filed by Savara Inc.
- Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
- Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
- Chief Fin. & Operating Officer Lutz Robert Matthew was granted 35,000 shares, increasing direct ownership by 12% to 328,977 units (SEC Form 4)
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Chief Financial Officer Lowrance David L exercised 580,187 shares at a strike of $1.76, covered exercise/tax liability with 185,659 shares and sold $2,241,432 worth of shares (394,528 units at $5.68) (SEC Form 4)
- Savara Announces New Employment Inducement Grant